The LentiVector Gene Therapy Platform for Ocular Disease: a clinical update Oxford BioMedica currently has three ocular therapies in clinical development using the LentiVector platform: RetinoStat, StarGenT and UshStat, for the treatment of age-related macular degeneration, Stargardt macula dystrophy and...
With the goal of creating antigen-directed immunotherapeutics that can be safely administered directly to patients, Immune Design has developed a platform of novel integration-deficient lentiviral vectors that target and deliver antigen-encoding nucleic acids to dendritic cells (DCs) in order to promote...
This platform, termed DCVex(TM), utilizes a novel genetic variant of a Sindbis virus envelope glycoprotein with post-translational carbohydrate modifications in combination with Vpx, a SIVmac viral accessory protein, to achieve efficient targeting and transduction of DCs. In addition, DCVex(TM) ...
The utility of blended microgel suspensions may provide an especially appealing platform for the delivery of lentivectors or similarly sized therapeutics.Madrigal, Justin L.Sharma, Shonit N.Campbell, Kevin T.Stilhano, Roberta S.Gijsbers, RikSilva, Eduardo A....